Lindsay Claxton

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 6

Top Topics

Rheumatoid Arthritis

Systematic Review

Ejection Fraction

Advanced Non Small Cell Lung Cancer

Top Venues

Health technology assessment (Winchester, England)

PharmacoEconomics

Journal of medical economics

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Lindsay Claxton, Mark Simmonds, Lucy Beresford, Richard M Cubbon, Mark Jeremy Dayer, Stephen S Gottlieb, Nick Hartshorne-Evans, Bruce Kilroy, Alexis Llewellyn, Claire Rothery, Sahar Sharif-Hurst, Jayne F Tierney, Klaus K Witte, Kath Wright, Lesley A Stewart
Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation. Health technology assessment (Winchester, England) 26 (4) (2022)
Peter Murphy, David Glynn, Sofia Dias, Robert Hodgson, Lindsay Claxton, Lucy Beresford, Katy Cooper, Paul Tappenden, Kate Ennis, Alessandro Grosso, Kath Wright, Anna Cantrell, Matthew D Stevenson, Stephen Palmer
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health technology assessment (Winchester, England) 25 (76) (2022)
Matthew Walton, Ros Wade, Lindsay Claxton, Sahar Sharif-Hurst, Melissa Harden, Jai Patel, Denis Moir, Robert Hodgson, Alison Eastwood
Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health technology assessment (Winchester, England) 24 (48) (2021)
Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, Kath Wright, Robert Hodgson
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. PharmacoEconomics 37 (5) (2020)
Der-Yuan Chen, Ping-Ning Hsu, Chao-Hsiun Tang, Lindsay Claxton, Satish Valluri, Robert A Gerber
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. Journal of medical economics 22 (8) (2019)
Lindsay Claxton, Matthew Taylor, Robert A Gerber, David Gruben, Dermot Moynagh, Amitabh Singh, Gene V Wallenstein
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Current medical research and opinion 34 (11) (2018)